Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414920 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
NCT01414920: Completed Phase 2 study, sponsored by Takeda.
NCT01414920 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 368 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01414920, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
Primary Outcome
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 relative to baseline.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG TAK-875
- DRUG TAK-875 and Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01414920 record still lists
NCT01414920 is an interventional study that assigns participants to a tested intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01414920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01414920 about?
NCT01414920 is a clinical study titled "Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01414920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2011-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01414920?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), TAK-875 (DRUG), TAK-875 and Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01414920?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01414920's enrollment target sits among peer trials
368 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia